Drug Profile
Interleukin-1 receptor antagonist gene therapy
Latest Information Update: 24 May 2007
Price :
$50
*
At a glance
- Originator University of Montreal
- Developer Nonindustrial source; University of Montreal
- Class Gene therapies
- Mechanism of Action Interleukin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 24 May 2007 Discontinued - Phase-I for Osteoarthritis in Germany (Intra-articular)
- 24 May 2007 Discontinued - Phase-I for Osteoarthritis in USA (Intra-articular)
- 24 May 2007 Discontinued - Preclinical for Osteoarthritis in Canada (Intra-articular)